Associated Papers
Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia.
Bárcenas-López DA et al.
Translational Oncology, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures.
Billon P et al.
Cell Reports, 2020
Ras pathway mutation feature in the same individuals at diagnosis and relapse of childhood acute lymphoblastic leukemia.
Zhang HH et al.
Translational Pediatrics, 2020
Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia.
Moriyama T et al.
Molecular Cancer Therapeutics, 2019
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL et al.
Cancer Cell, 2018
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G et al.
Nature, 2018
Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia.
Hnízda A et al.
Bmc Biology, 2016
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G et al.
Nature Medicine, 2013
Therapeutic resistance: ALL-important mutations.
Seton-Rogers S
Nature Reviews. Cancer, 2013
Select a paper to view details